Adjuvant Therapy in mRCC
Adjuvant Therapy in mRCC
Prof. Sandy Srinivas
This month Prof. Sandy Srinivas and Dr. Roberto Iacovelli provide their thoughts and views on: Adjuvant Therapy in mRCC
Prof. Sandy Srinivas
Medical Oncologist
Stanford University Medical Center
United States (US)
| 
5 min
|
2017
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Emerging treatments from multiple drug trials
Medical Oncologists, Prof. Sandy Srinivas and Dr. Roberto Iacovelli, discuss the use of adjuvant therapy in metastatic renal cell carcinoma (mRCC). Discussion centres on drug trials, in particular, comparison of the ASSURE trial and the S-TRAC TRIAL. The ASSURE trial is a study of VEGF receptor tyrosine kinase inhibitors, sorafenib and sunitinib, and examines disease free survival as a primary endpoint. The S-TRAC trial is a study of the effect of sunitinib in treatment of clear-cell RCC, looking at disease free survival and overall survival. Our experts explore the differences between these two studies and cover details of other trials including the PROTECT trial of Pazopanib treatment in clear-cell RCC, and several other trials pertinent to adjuvant therapy in kidney cancer. Please explore the slides and watch the video to gain the latest clinical insights on adjuvant therapy in mRCC.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.
Other programmes of interest
28 min
Other programmes developed by Prof. Sandy Srinivas
Prof. Sandy Srinivas
Medical Oncologist
Stanford University Medical Center
United States (US)
